These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35793473)

  • 1. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ.
    Curmin R; Guillo S; De Rycke Y; Bachelez H; Beylot-Barry M; Beneton N; Chosidow O; Dupuy A; Joly P; Jullien D; Richard MA; Viguier M; Sbidian E; Paul C; Mahé E; Tubach F;
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2101-2112. PubMed ID: 35793473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching biologics in children with psoriasis: Results from the BiPe cohort.
    Phan C; Beauchet A; Reguiai Z; Severino-Freire M; Mazereeuw-Hautier J; Bursztejn AC; Barbarot S; Hadj-Rabia S; Girard C; Phan A; Lacour JP; Lasek A; Abasq C; Brenaut E; Perrussel M; Droitcourt C; Mallet S; Piram M; Fougerousse AC; Barthélémy H; Balguérie X; Mahé E;
    Pediatr Dermatol; 2022 Jan; 39(1):35-41. PubMed ID: 34888920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
    Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
    J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Iskandar IYK; Warren RB; Lunt M; Mason KJ; Evans I; McElhone K; Smith CH; Reynolds NJ; Ashcroft DM; Griffiths CEM;
    J Invest Dermatol; 2018 Apr; 138(4):775-784. PubMed ID: 29080680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short "Washout" Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy.
    Tampouratzi E; Sfaelos K; Talaiporou K; Douvali Τ; Katsantonis J
    Acta Dermatovenerol Croat; 2023 Aug; 31(1):48-50. PubMed ID: 37843093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis.
    Gooderham MJ; Lynde C; Turchin I; Avadisian M; Labelle M; Papp KA
    J Dermatol; 2022 Jan; 49(1):95-105. PubMed ID: 34747071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
    Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching of biologics in psoriasis: Reasons and results.
    Honda H; Umezawa Y; Kikuchi S; Yanaba K; Fukuchi O; Ito T; Nobeyama Y; Asahina A; Nakagawa H
    J Dermatol; 2017 Sep; 44(9):1015-1019. PubMed ID: 28488283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Iskandar IYK; Ashcroft DM; Warren RB; Evans I; McElhone K; Owen CM; Burden AD; Smith CH; Reynolds NJ; Griffiths CEM
    Br J Dermatol; 2017 May; 176(5):1297-1307. PubMed ID: 27589476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence Among Patients with Crohn Disease Previously Treated with an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent.
    Zhdanava M; Kachroo S; Manceur AM; Ding Z; Holiday C; Zhao R; Godwin B; Pilon D
    Clin Ther; 2023 Aug; 45(8):770-777. PubMed ID: 37442653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort.
    Sbidian E; Giboin C; Bachelez H; Paul C; Beylot-Barry M; Dupuy A; Viguier M; Lacour JP; Schmutz JL; Bravard P; Mahé E; Beneton N; Misery L; Delaporte E; Modiano P; Barbarot S; Regnier E; Jullien D; Richard MA; Joly P; Tubach F; Chosidow O
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2046-2054. PubMed ID: 28609574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
    Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB
    J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Dand N; Barker JN; Smith CH; Griffiths CEM;
    Br J Dermatol; 2024 Apr; 190(5):689-700. PubMed ID: 38051972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age and psoriatic arthritis are important predictors of biologic agent switch in psoriasis.
    Akdogan N; Dogan S; Bostan E; Gulseren D; Yalici-Armagan B; Elcin G; Evans SE; Karaduman A; Atakan N
    Expert Rev Clin Pharmacol; 2021 Dec; 14(12):1535-1541. PubMed ID: 34519227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq.
    Assan F; Tubach F; Arlegui H; Viguier M; Beylot-Barry M; Dupuy A; Beneton N; Joly P; Jullien D; Mahé E; Paul C; Richard MA; Bachelez H; Giboin C; Chosidow O; Sbidian E;
    Dermatology; 2021; 237(3):338-346. PubMed ID: 33535213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study.
    Schwarz CW; Loft N; Rasmussen MK; Nissen CV; Dam TN; Ajgeiy KK; Egeberg A; Skov L
    Acta Derm Venereol; 2021 Oct; 101(10):adv00579. PubMed ID: 34642768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.
    Puig L; Carrascosa JM; Daudén E; Sulleiro S; Guisado C
    J Dermatolog Treat; 2020 Jun; 31(4):344-351. PubMed ID: 30888880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.